Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Investor Presentation (June 2010)
33 slides from Cytosorbents's investor presentation, Jun 29, 2010
Slide 1: CytoSorbents
cytoSorhen ints ¢
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiary CytoSorbents, Inc that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ m
Slide 3: CytoSorbents Overview
S Overview iS is a critical care-focused device company using blood purification to treat disease The heart of the technology is a biocompatible, highly porous, polymer bead that can remove a wide range of toxic substances such as drugs, cytokines, and toxins from blood and physiologic fluids based
Slide 4: Concept is Simple But Elegant
Concept is Simple But Elegant The polymer beads are packed into hemoperfusion cartridges compatible with standard hemodialysis machines Obtain venous access with temporary dialysis catheter Pump blood through the cartridge with standard pumps The polymer beads remove toxic substances “Purified” bloo
Slide 5: Management Team
Management Team Phillip Chan, MD, PhD — Chief Executive Officer and President Board-certified internal medicine physician. MD/PhD from Yale School of Medicine. Internal Medicine residency at the Beth Israel Deaconess Medical Center at Harvard. Former Partner at NJTC Venture Fund heading up healthcar
Slide 6: Medical Advisory Board
Medical Advisory Board John Kellum, MD Professor of Critical Care Medicine & Anesthesiology University of Pittsburgh Medical Center Chair of the Sepsis Advisory Board Emil Paganini, MD Former Section Head of Dialysis and Extracorporeal Therapy with the Cleveland Clinic Foundation Joseph Parrillo, MD
Slide 7: Critical Care Is a Lucrative Market
Critical Care Is a Lucrative Market Even with healthcare reform, critical care will likely remain a lucrative market ripe for cost-effective therapies ¢ Treatment of critical care patients is extremely costly and is a major pain point for hospitals “Need to have’ life-saving therapies command signif
Slide 8: Critical Care Lacks "Active" Therapies
Critical Care Lacks “Active” Therapies There are few “active” therapies available for serious diseases seen in the intensive care unit Severe sepsis and septic shock Acute respiratory distress syndrome (ARDS) Burn and smoke inhalation injury Trauma Influenza Consequences of cardiac surgery Severe ac
Slide 9: But Treatment Today is Mainly Supportive
But Treatment Today is Mainly Supportive Patients have a very high risk of death due to multi-organ failure and infection Aside from antibiotics, current standard of care treatment is mainly supportive care that helps keep the patient alive, but does not necessarily hasten recovery or reverse the or
Slide 10: CytoSorbents is a Critical Care Pure Play
; is a Critical Care Pure Play The cornerstone of our strategy to “actively treat” critical care diseases is An efficient cytokine filter that can potentially reduce deadly inflammation caused by Cytokine Storm
Slide 11: Cytokines: A Dual-Edged Sword
Cytokines: A Dual-Edged Sword * Cytokines are small proteins that, in moderation, normally help stimulate and regulate the immune system. They are required for proper immune system function ¢ Pro-inflammatory cytokines are up-regulated in inflammation, infection and trauma ¢ Anti-inflammatory cytoki
Slide 12: Cytokine Storm Leads to Organ Failure
Cytokine Storm Leads to Organ Failure = CC , Intestinal Clotting / | | ee Injury Immune Siieek Paralysis Lung Injury! Cell Death _ Inflammation, Organ Failure and Infe ection _|
Slide 13: Cytokine Storm in Action
Cytokine Storm in Action TeGenero Anti-CD28 monoclonal antibody Phase | Trial Designed to stimulate the immune system to treat cancer Phase | safety trial (2006) — 6 healthy adult males * 90 minutes: All had systemic inflammatory response Headache, nausea, muscle pain, diarrhea, hypotension * 12-16
Slide 14: Cytokine Storm Plays a Pivotal Role
Cytokine Storm Plays a Pivotal Role Severe _ Burns Sepsis Inhalation ARDS/ALI \ or Biowarfare \ Influenza Cytokine - Inflammation _ Cardiac SIRS/Sepsis ~ Surgery { Poor clinical outcome, Organ failure, Death
Slide 15: Treating Cytokine Storm — The Holy Grail
Treating Cytokine Storm — The Holy Grail Reduction in Cytokine Storm has been the target of the industry for three decades ¢ Unfortunately, most drugs and biologics can only reduce a single cytokine or inflammatory mediator « Too much redundancy in the immune system for this strategy to work A Broad
Slide 16: Simulated for illustrative purposes only
Simulated for illustrative Purposes only. é we ZS 8 co CytoSorbents
Slide 17: CytoSorb Active in Cytokine Sweet Spot
»Sorb" Active in Cytokine Sweet Spot 18 IL-1p HMGB1 TNF-a monomer TGF-B IFN-y. ene IL-6 ; sFas sTN MCP-1 glycosylated IFN-y dimer kDa 0 10 ——) Hemodialysis loSorbents
Slide 18: CytoSorb State of the Art Technology
Sorhis State of the Art Technology Very efficient at removing cytokines from whole blood Biocompatible and hemocompatible — ISO 10993 Massive capacity Easier to use than dialysis Compatible with standard hospital dialysis equipment Inherently high gross margins Long shelf life
Slide 19: Manufacturing Capabilities
Manufacturing Capabilities* CytoSorbents manufactures its own polymer and devices with several thousand made to date Manufacturing is a Mature and Scalable Process Polymer manufacturing facility in New Jersey Well-documented, reproducible production Polymer, device fill and packaging validated to me
Slide 20: The Sepsis Problem
The Sepsis Severe sepsis and septic shock are often the result of an “overwhelming infection” Afflicts 18 million people worldwide every year and is growing Kills 1 in every 3 despite the best medical treatment Kills more people in the U.S. than either heart attacks, strokes, or any single type of c
Slide 21: CytoSorb Has Strong Pre-clinical Data
Has Strong Pre-clinical Data removes cytokines in vitro and in simulated whole blood circulation systems on the order of 80-95% significantly improves survival in animal models of sepsis treatment was safe in more than 160 canine treatments helped stabilize a 71 year old man in septic shock from gan
Slide 22: Example of IL-6 Removal from Whole Blood
Example of IL-6 Removal from Whole Blood Control vs. Arterial vs. Venous [11-6] (py/mL) 100 Minutes In vitro circulation system scaled for human treatment
Slide 23: CytoSorb improves survival in animals
CytoSorb improves survival in animals "0 120 240 360 480 600 720 Time (min) CytoSorb Survival = 7/20 vs 1/20 for sham Kellum, JA, Song M, Venkataraman, R “Hemoadsorption removes TNF, IL-6, and IL-10, reduces NF-KB DNA binding, and improves short-term survival in lethal endotoxemia” Crit Care Med (20
Slide 24: ..with prevention of shock
.. with prevention of shock Effects of hemoadsorption on mean arterial pressure CytoSorb (MAP) (Mean +/- SEM, mm Hg) in the CLP rat sepsis model. Hemoadsorption is shown in the dashed line while sham results are shown in the solid line. MAP was significantly different over time and between groups (p
Slide 25: ..and reduction of cytokines
..and reduction of cytokines CLP Animal Model Cytokine Data > ‘THF (in poll) Peng, ZY, Carter, MJ, Kellum, JA “Effects of hemoadsorption on cytokine Black bars = CytoSorb removal and short term survival in rats” Crit Care Med (2008) 36(5): 1573-7 White bars = Sham Gytosorbe
Slide 26: CytoSorb also decreases activity of NF-kB
also decreases activity of NF-kB CytoSorb reduces activity of NF-«B, a major inflammatory transcription factor and driver of cytokine production Endotoxin Challenge Model NF-«B activity in the livers of CytoSorb or sham-treated animals following 4 hours of treatment as determined by nuclear extract
Slide 27: Positive Human Proof-of-Concept
Positive Human Proof-of-Concept Conducted a human sepsis pilot comparing standard of care therapy versus standard of care plus Sorb treatment in patients with severe sepsis and respiratory failure « All data from a single major academic site (6 treated, 6 control) demonstrated substantial improvemen
Slide 28: European Sepsis Trial
European Sepsis Trial ¢ Conducting a 100 patient randomized, controlled Clinical trial to treat patients with severe sepsis in the setting of respiratory failure ¢ Enrollment is currently 70% of target * Comparing standard of care therapy alone with standard of care therapy plus treatment * Treatmen
Slide 29: CytoSorb — A Powerful New Approach
Sorh™ — A Powerful New Approach Sorb has the potential to help save lives by reducing the cytokine storm that leads to multi-organ failure from many causes Severe : Influenza Sepsis Cardiac Sorh’ Biowarfare Surgery Trauma Burns ARDS/ALI
Slide 30: CytoSorb Seeks Strategic Alliances
Seeks Strategic Alliances seeks partners for its growth technology portfolio that is protected by 27 issued patents and multiple applications pending has blockbuster potential as a cytokine filter US and EU total addressable market for these apps is ~ $10-15 billion Limited competition Differentiate
Slide 31: CytoSorbents Pipeline
CytoSorbents Pipeline CyloSerbents has a robust, innovative pipeline with NAME INDICATION DESCRIPTION STATUS CytoSorb™ | Severe sepsis Highly efficient cytokine filter that is Registration clinical designed to treat cytokine storm in sepsis | trial in Europe BetaSorb™ _ | Improvement of hemodialysis
Slide 32: CytoSorbents Goals and Milestones 2010-11
Sorhents Goals and Milestones 2010-11 Successful trial completion CE Mark approval Commercial sales in Europe Out-licensing the sepsis application Out-licensing of other non-core applications Commencement of a US trial Expansion of pipeline opportunities loSorbents
Slide 33: Contact
Through Phillip P. Chan, MD, PhD CEO and President 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 (732) 329-8885 pchan@cytosorbents.com